382 related articles for article (PubMed ID: 27476707)
21. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy.
Iwamoto J; Saito Y; Honda A; Matsuzaki Y
World J Gastroenterol; 2013 Mar; 19(11):1673-82. PubMed ID: 23555156
[TBL] [Abstract][Full Text] [Related]
22. What is the long term acid inhibitor treatment in gastroesophageal reflux disease? What are the potential problems related to long term acid inhibitor treatment in gastroesophageal reflux disease? How should these cases be followed?
Hatemi İ; Esatoğlu SN
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S57-S60. PubMed ID: 29199170
[TBL] [Abstract][Full Text] [Related]
23. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
24. Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study.
Wada Y; Ito M; Takata S; Kitamura S; Takamura A; Tatsugami M; Imagawa S; Matsumoto Y; Tanaka S; Yoshihara M; Chayama K
Hepatogastroenterology; 2009; 56(91-92):624-8. PubMed ID: 19621668
[TBL] [Abstract][Full Text] [Related]
25. Optimal management of peptic ulcer disease in the elderly.
Pilotto A; Franceschi M; Maggi S; Addante F; Sancarlo D
Drugs Aging; 2010 Jul; 27(7):545-58. PubMed ID: 20583849
[TBL] [Abstract][Full Text] [Related]
26. [Long-term use of proton pump inhibitors: who needs prophylaxis?].
Scheurlen M
Internist (Berl); 2013 Mar; 54(3):366-72. PubMed ID: 23404267
[TBL] [Abstract][Full Text] [Related]
27. [Curative and preventive treatment of NSAID-associated gastroduodenal ulcers].
Dupas JL; Grigy C
Gastroenterol Clin Biol; 2004 Apr; 28 Spec No 3():C77-83. PubMed ID: 15366678
[TBL] [Abstract][Full Text] [Related]
28. Do recent reports about the adverse effects of proton pump inhibitors change providers' prescription practice?
Al-Qaisi MT; Kahn A; Crowell MD; Burdick GE; Vela MF; Ramirez FC
Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29873678
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.
Sun S; Cui Z; Zhou M; Li R; Li H; Zhang S; Ba Y; Cheng G
Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27577963
[TBL] [Abstract][Full Text] [Related]
30. Safety of the long-term use of proton pump inhibitors.
Thomson AB; Sauve MD; Kassam N; Kamitakahara H
World J Gastroenterol; 2010 May; 16(19):2323-30. PubMed ID: 20480516
[TBL] [Abstract][Full Text] [Related]
31. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
;
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
[TBL] [Abstract][Full Text] [Related]
32. Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: a systematic review.
Nagaraja V; Eslick GD
World J Gastroenterol; 2014 Oct; 20(40):14527-36. PubMed ID: 25356018
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
34. Therapy for peptic ulcer disease.
Lukáš M
Vnitr Lek; 2018; 64(6):595-599. PubMed ID: 30223656
[TBL] [Abstract][Full Text] [Related]
35. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
36. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding.
Neumann I; Letelier LM; Rada G; Claro JC; Martin J; Howden CW; Yuan Y; Leontiadis GI
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD007999. PubMed ID: 23760821
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
[TBL] [Abstract][Full Text] [Related]
38. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
Robinson M
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
[TBL] [Abstract][Full Text] [Related]
39. [Current use of proton pump inhibitors and when to limit, stop or not start treatment].
Helgadottir H; Bjornsson ES
Laeknabladid; 2023 Jul; 109(708):338-345. PubMed ID: 37378651
[TBL] [Abstract][Full Text] [Related]
40. What you should know about: PPIs.
Harv Health Lett; 2013 Feb; 38(4):7. PubMed ID: 23841173
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
